By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Kancera 

2010 Kancera Ab
Karolinska Institutet Science Park, Banvaktsvägen 22
Solna    171 48   Sweden
Phone: n/a Fax: n/a


SEARCH JOBS

Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, by regulating the immune system, blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 18 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7500 as of June 30th, 2017. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.

YEAR FOUNDED:

2010

LEADERSHIP:

CEO: Thomas Olin


Key Statistics


Email:
Ownership: Private

Web Site: Kancera
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->